Phase 2 MIRA primary analysis trial results (12-week) for MoonLake’s Nanobody® sonelokimab in hidradenitis suppurativa to be presented at a late-breaking session at the European Academy of Dermatology and Venereology Congress ZUG, Switzerland, October 4, 2023 – MoonLake Immunotherapeutics AG (“MoonLake”; Nasdaq: MLTX), a clinical-stage biotechnology company focused on creating next-level therapies for inflammatory diseases, today announces that 12-week Phase 2 MIRA trial data for the Nanobody® sonelokimab in hidradenitis suppurativa will be presented at the European Academy of Dermatology and Venereology Congress taking place from October 11-14 in Berlin, Germany.

第2阶段MIRA初步分析试验结果（12周），MoonLake的Nanobody®sonelokimab在化脓性汗腺炎中的应用将于2023年10月4日在瑞士祖格欧洲皮肤性病学会大会的最后一次会议上发表-MoonLake Immunotherapeutics AG（“MoonLake”；纳斯达克股票代码：MLTX），一家专注于为炎症性疾病创造下一级疗法的临床阶段生物技术公司今天宣布，化脓性汗腺炎中Nanobody®sonelokimab的12周2期MIRA试验数据将于10月11日至14日在德国柏林举行的欧洲皮肤病学和性病学会大会上公布。

In June 2023, MoonLake announced positive topline 12-week Phase 2 MIRA trial results, achieving a landmark milestone as the first placebo-controlled randomized trial in HS to report positive top-line results using HiSCR75 as the primary endpoint. Professor Brian Kirby MD, FRCPI, Charles Department of Dermatology, St.

2023年6月，MoonLake宣布12周的MIRA临床试验结果为阳性，这是HS首个安慰剂对照随机试验的里程碑式里程碑，以HiSCR75为主要终点报告阳性的一线结果。St.Charles皮肤科FRCPI教授Brian Kirby教授。

Vincent’s University Hospital and Charles Institute of Dermatology, University College Dublin, Dublin, Ireland will be presenting the results in a late-breaking news presentation, details of which are included below. Session code and title: D1T01.1: Late breaking newsLocation: Hall BDate and time: Wednesday, 11 October; session 14.15 - 17.30 CEST, presentation 16.15 - 16.30 CESTPresentation title: Efficacy and safety of the IL-17A- and IL-17F-inhibiting Nanobody® sonelokimab in patients with active, moderate-to-severe hidradenitis suppurativa: Results from the global, randomized, double-blind, placebo-controlled Phase 2 MIRA trial The 24-week Phase 2 MIRA trial data for Nanobody® sonelokimab in hidradenitis suppurativa is anticipated imminently.

爱尔兰都柏林都柏林大学学院文森特大学医院和查尔斯皮肤病研究所将在最新新闻报道中介绍结果，详情如下。会议代码和标题：D1T01.1：最新消息位置：大厅日期和时间：10月11日星期三；会议14.15-17.30 CEST，演讲16.15-16.30 CEST演讲题目：IL-17A和IL-17F抑制Nanobody®sonelokimab在活动性，中度至重度化脓性汗腺炎患者中的疗效和安全性：来自全球，随机，双盲，安慰剂对照的2期MIRA试验预计Nanobody®sonelokimab在化脓性汗腺炎中的24周2期MIRA试验数据即将公布。

In addition, top-line 12-week results for MoonLake’s.

此外，MoonLake的顶级12周结果。